Cargando…

The Kinase Specificity of Protein Kinase Inhibitor Peptide

G-protein-coupled-receptor (GPCR) signaling is exquisitely controlled to achieve spatial and temporal specificity. The endogenous protein kinase inhibitor peptide (PKI) confines the spatial and temporal spread of the activity of protein kinase A (PKA), which integrates inputs from three major types...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Yao, Sabatini, Bernardo L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7878667/ https://www.ncbi.nlm.nih.gov/pubmed/33584320 http://dx.doi.org/10.3389/fphar.2021.632815

Ejemplares similares

Protein Kinase Inhibitor Peptide as a Tool to Specifically Inhibit Protein Kinase A
por: Liu, Chong, et al.
Publicado: (2020)

Predicting individual-specific cardiotoxicity responses induced by tyrosine kinase inhibitors
por: Shim, Jaehee V., et al.
Publicado: (2023)

Advances in RIPK1 kinase inhibitors
por: Chen, Lu, et al.
Publicado: (2022)

Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Associated Cardiotoxicity: A Recent Five-Year Pharmacovigilance Study
por: Liu, Yihan, et al.
Publicado: (2022)

Development of Certain Protein Kinase Inhibitors with the Components from Traditional Chinese Medicine
por: Liu, Minghua, et al.
Publicado: (2017)

Safety and efficacy of p38 mitogen-activated protein kinase inhibitors (MAPKIs) in COPD
por: Yu, Haichuan, et al.
Publicado: (2022)

Erratum: Advances in RIPK1 kinase inhibitors
Publicado: (2023)

Rho-Associated Protein Kinase Inhibitor Treatment Promotes Proliferation and Phagocytosis in Trabecular Meshwork Cells
por: Chen, Wenshi, et al.
Publicado: (2020)

U0126: Not only a MAPK kinase inhibitor
por: You, Yijie, et al.
Publicado: (2022)

Corrigendum: Eupafolin Suppresses Esophagus Cancer Growth by Targeting T-LAK Cell-Originated Protein Kinase Protein Kinase
por: Fan, Xiaoming, et al.
Publicado: (2020)

FGIN-1-27 Inhibits Melanogenesis by Regulating Protein Kinase A/cAMP-Responsive Element-Binding, Protein Kinase C-β, and Mitogen-Activated Protein Kinase Pathways
por: Lv, Jinpeng, et al.
Publicado: (2020)

Usage of Mitogen-Activated Protein Kinase Small Molecule Inhibitors: More Than Just Inhibition!
por: Meurer, Steffen K., et al.
Publicado: (2018)

Kinase Inhibitors as Potential Therapeutic Agents in the Treatment of COVID-19
por: Naik, Rajashri R., et al.
Publicado: (2022)

Drug resistance mechanism of kinase inhibitors in the treatment of hepatocellular carcinoma
por: Jiang, Lei, et al.
Publicado: (2023)

Exploring the chemotherapeutic potential of currently used kinase inhibitors: An update
por: Naik, Rajashri R., et al.
Publicado: (2023)

Target Specific Inhibition of Protein Tyrosine Kinase in Conjunction With Cancer and SARS-COV-2 by Olive Nutraceuticals
por: Ghosh, Arabinda, et al.
Publicado: (2022)

Mechanisms for redox-regulation of protein kinase C
por: Steinberg, Susan F.
Publicado: (2015)

Commentary: Usage of Mitogen-Activated Protein Kinase Small Molecule Inhibitors: More Than Just Inhibition!
por: Pollet, Marius, et al.
Publicado: (2018)

Protein phosphatase 6 regulates trametinib sensitivity, a mitogen-activated protein kinase kinase (MEK) inhibitor, by regulating MEK1/2-ERK1/2 signaling in canine melanoma cells
por: YAMAMOTO, Miu, et al.
Publicado: (2023)

Icotinib derivatives as tyrosine kinase inhibitors with anti-esophageal squamous carcinoma activity
por: Chen, Xiaojie, et al.
Publicado: (2022)

Cyclin-Dependent Kinase Inhibitors and Their Therapeutic Potential in Colorectal Cancer Treatment
por: Thoma, Oana-Maria, et al.
Publicado: (2021)

Model-Based Biomarker Selection for Dose Individualization of Tyrosine-Kinase Inhibitors
por: Centanni, Maddalena, et al.
Publicado: (2020)

Erratum: Drug resistance mechanism of kinase inhibitors in the treatment of hepatocellular carcinoma
por: Frontiers Production Office,
Publicado: (2023)

Identification of potential extracellular signal-regulated protein kinase 2 inhibitors based on multiple virtual screening strategies
por: Yang, Ruoqi, et al.
Publicado: (2022)

Involvement of Phosphatase and Tensin Homolog in Cyclin-Dependent Kinase 4/6 Inhibitor-Induced Blockade of Glioblastoma
por: Liu, Songlin, et al.
Publicado: (2019)

Counteracting Protein Kinase Activity in the Heart: The Multiple Roles of Protein Phosphatases
por: Weber, Silvio, et al.
Publicado: (2015)

Targeting protein–protein interactions in complexes organized by A kinase anchoring proteins
por: Calejo, Ana I., et al.
Publicado: (2015)

The Bruton’s Tyrosine Kinase Inhibitor Ibrutinib Impairs the Vascular Development of Zebrafish Larvae
por: Wang, Kun, et al.
Publicado: (2021)

Inflammation Resolution and the Induction of Granulocyte Apoptosis by Cyclin-Dependent Kinase Inhibitor Drugs
por: Cartwright, Jennifer A., et al.
Publicado: (2019)

Hepatocellular Toxicity Associated with Tyrosine Kinase Inhibitors: Mitochondrial Damage and Inhibition of Glycolysis
por: Paech, Franziska, et al.
Publicado: (2017)

Src Tyrosine Kinase Inhibitors: New Perspectives on Their Immune, Antiviral, and Senotherapeutic Potential
por: Rivera-Torres, José, et al.
Publicado: (2019)

Clinical updates on tyrosine kinase inhibitors in HER2-positive breast cancer
por: Singh, Desh Deepak, et al.
Publicado: (2022)

Serum and glucocorticoid-regulated kinase 1: Structure, biological functions, and its inhibitors
por: Jang, Hyunsoo, et al.
Publicado: (2022)

Editorial: Pharmacological and biochemical perspectives of kinase inhibitors in cancer and COVID-19 therapeutics
por: Chandrasekaran, Balakumar, et al.
Publicado: (2023)

Potential Role of Protein Kinase C in the Pathophysiology of Diabetes-Associated Atherosclerosis
por: Lien, Chih-Feng, et al.
Publicado: (2021)

HSP90 Inhibitor Ganetespib Enhances the Sensitivity of Mantle Cell Lymphoma to Bruton’s Tyrosine Kinase Inhibitor Ibrutinib
por: Lu, Ziwen, et al.
Publicado: (2022)

Receptor Interacting Protein Kinases 1/3: The Potential Therapeutic Target for Cardiovascular Inflammatory Diseases
por: Leng, Yiming, et al.
Publicado: (2021)

Immunomodulatory Activity of Tyrosine Kinase Inhibitors to Elicit Cytotoxicity Against Cancer and Viral Infection
por: Climent, Núria, et al.
Publicado: (2019)

Natural Kinase Inhibitors for the Treatment and Management of Endometrial/Uterine Cancer: Preclinical to Clinical Studies
por: Singla, Rajeev K., et al.
Publicado: (2022)

Study on the Characteristics of Small-Molecule Kinase Inhibitors-Related Drug-Induced Liver Injury
por: Dong, Huiqun, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_30ge9ckhhgaijfvv0o1aek0vtq